Minimal Residual Disease

SAN FRANCISCO — The addition of cabazitaxel to neoadjuvant abiraterone acetate did not improve tumor response among men with high-risk prostate cancer, according to randomized phase 2 study results presented at ASCO Genitourinary Cancers Symposium.

Minimal residual disease status appeared to influence outcomes after chimeric antigen receptor T-cell therapy for high-risk chronic lymphocytic leukemia, according to study results.

The addition of isatuximab to a standard three-drug induction regimen improved outcomes for certain patients with multiple myeloma, according to randomized phase 3 study results presented at ASH Annual Meeting and Exposition.

Using circulating tumor DNA to predict relapse after autologous stem cell transplantation in patients with multiple myeloma showed feasibility in a study presented at the virtual ASCO Annual Meeting.

The combination of daratumumab, carfilzomib, lenalidomide and dexamethasone conferred high rates of minimal residual disease negativity among patients with newly diagnosed multiple myeloma, according to phase 2 study results.

Caloric restriction through diet and exercise appeared to enhance the efficacy of chemotherapy among young patients with B-cell acute lymphoblastic leukemia, according to results of the IDEAL study published in Blood Advances.

Detection of circulating tumor DNA using immunoglobulin-based next generation sequencing within an apheresis stem cell sample predicted relapse after autologous stem cell transplantation among patients with diffuse large B-cell lymphoma.

Patients with chronic lymphocytic leukemia with undetectable minimal residual disease after first-line venetoclax plus ibrutinib achieved similar 1-year DFS whether they then received ibrutinib or placebo, according to study results.

A combination of obinutuzumab, ibrutinib and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia, according to study results published in Journal of Clinical Oncology.

Children with very low-risk acute lymphoblastic leukemia can be treated successfully with reduced-intensity therapy, according to results of a study published in Blood.